Key challenges for drugs in clinical development for cholangiocarcinoma

References

• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111.
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma Incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–599.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588.
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–114.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–830.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Goff LW, Keenan BP, et al. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer. 2019;125(24):4426–4434.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J clin oncol. 2019;37(15_suppl):4003.
   Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nature Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al., TAS-120 overcomes Resistance to ATP-Competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9(8): 1064–1079. 2019. .
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684.
   PubMed Web of Science ®Google Scholar
• Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–765.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res off J Am Assoc Cancer Res. 2018;24(17):4154–4161. .
   PubMed Web of Science ®Google Scholar
• Subbiah V, Puzanov I, Blay JY, et al. Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers. Cancer Discov. 2020;10(5):657–663. .
   PubMed Web of Science ®Google Scholar
• Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res off J Am Assoc Cancer Res. 2018;24(23):5807–5814.
   PubMed Web of Science ®Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PloS One. 2014;9(12):e115383.
   PubMed Web of Science ®Google Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh D-Y, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. International Journal of Cancer. 2020;147(8):2. .
   Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncology. 2020;6(6):888–894. .
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih MG, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158. Ann Oncol. 2019;30(Suppl. 5):v477–v478.
   Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. .
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology. 2019;25.
   Google Scholar
• Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–429.
   PubMed Web of Science ®Google Scholar
• Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360:6391.
   Web of Science ®Google Scholar
• Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J clin oncol. 2020;38(31):3698–3715.
   PubMed Web of Science ®Google Scholar
• Valle JW, Bai L-Y, Orlova R, et al. Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. J clin oncol. 2020;38(4_suppl):477.
   Web of Science ®Google Scholar
• Phelip JM, Edeline J, Blanc JF, et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II/III study. Dig Liver Dis. 2019;51(2):318–320.
   PubMedGoogle Scholar
• Burd A, Schilsky RL, Byrd JC, et al. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019;3(14):2237–2243.
   PubMed Web of Science ®Google Scholar
• FDA. Rare diseases: natural history studies for drug development; draft guidance for industry; availability. Office of the commissioner, office of clinical policy and programs, office of orphan products development, et al., editors. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Office of Orphan Products Development (OOPD). 2019: 1–19. https://www.fda.gov/media/122425/download2019
   Google Scholar
• Zill OA, Greene C, Sebisanovic D, et al. Cell-Free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015;5(10):1040–1048.
   PubMed Web of Science ®Google Scholar
• Peraldo-Neia C, Scatolini M, Grosso E, et al. Assessment of a high sensitivity method for identification of IDH1 R132x mutations in tumors and plasma of intrahepatic cholangiocarcinoma patients. Cancers (Basel). 2019;11:4.
   Web of Science ®Google Scholar
• Shen N, Zhang D, Yin L, et al. Bile cellfree DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer. Oncol Rep. 2019;42(2):549–560.
   PubMed Web of Science ®Google Scholar